Investigation on Advanced Non-Small-Cell Lung Cancer among Elderly Patients Treated with Chinese Herbal Medicine versus Chemotherapy: A Pooled Analysis of Individual Data

Table 4

Hazard ratios for relative survival of CHM and CT groups in selected subgroups.

	Unadjusted HR; (95% CI)	p-value	Adjusted HR; (95% CI)	p-value
Pathology
Non-SQCC	1.01 (0.86,1.19)	0.906	1.01(0.85, 1.19)	0.918
SQCC	0.97 (0.83,1.14)	0.736	1.02 (0.86, 1.21)	0.792
Stage
III	0.91 (0.74,1.12)	0.357	0.92 (0.74,1.14)	0.429
IV	1.01 (0.88,1.16)	0.859	0.99 (0.86,1.15)	0.928
Smoking Status
Non-smokers	0.95 (0.81,1.12)	0.563	0.97 (0.82,1.15)	0.720
Smokers	1.02 (0.98,1.20)	0.802	1.01 (0.86,1.20)	0.876
KPS
60-70	0.91 (0.76, 1.10)	0.360	0.92 (0.76, 1.11)	0.364
⩾80	1.02 (0.88, 1.17)	0.835	1.07 (0.92 1.25)	0.368
Age
60-70	0.96 (0.83, 1.11)	0.568	0.97 (0.83, 1.13)	0.669
>70	0.97 (0.80, 1.17)	0.732	0.98 (0.81, 1.19)	0.857
Previous Treatment
No	1.07 (0.93, 1.24)	0.338	1.08 (0.94, 1.25)	0.290
Yes	0.80 (0.66, 0.97)	0.022	0.83 (0.68, 1.01)	0.063

Note: a: stratified by studies and multivariate Cox model adjusted for smoking status, KPS, stage, and previous treatment; b: stratified by studies and adjusted for smoking status, pathology, and previous treatment; c: stratified by studies and adjusted for stage, KPS, and previous treatment; d: stratified by studies and adjusted for smoking status, stage, and previous treatment; e: stratified by studies and adjusted for smoking status, stage, and KPS. SQCC, squamous cell carcinoma; KPS, Karnofsky performance scores; CHM, Chinese herbal medicine; CT, chemotherapy; HR, hazard ratio; CI, confidence intervals.